SynthesisAnnals of nuclear medicine2021
[18F]FDG PET/MRI in rectal cancer.
Synthesis in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- FDG-PET/MRI in colorectal cancer care: an updated systematic review.Abdominal radiology (New York) · 2025Pooled it
- Head-to-head comparison ofDiagnostic and interventional radiology (Ankara, Turkey) · 2024Pooled it
- Diagnostic performance of whole-body [European radiology · 2024Pooled it
- Lymph nodes primary staging of colorectal cancer in 18F-FDG PET/MRI: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Diagnostic performance of [European journal of nuclear medicine and molecular imaging · 2022Pooled it
- Evaluating the usefulness of 18F-FDG PET/MR in rectal cancer staging: a prospective comparison with histopathological findings.International journal of colorectal disease · 2026Article
- Reimagining Nodal Staging in Colorectal Cancer: Toward a Novel Non-Invasive Imaging Approach.Cancers · 2026Review
- Multimodal radiomics for precision management of colorectal cancer.Discover oncology · 2026Review
- Clinical utility and future directions of FDG-PET in rectal cancer management.Annals of nuclear medicine · 2026Review
- MRI's evolving role in rectal cancer in the era of personalized medicine.Abdominal radiology (New York) · 2026Review
- Diagnostic Performance of [World journal of nuclear medicine · 2025Review
- The Application of Combined PET/MRI in Staging and Response Assessment of Rectal Cancer.Journal of clinical medicine · 2025Review
- PET/MRI: pictorial review of hepatobiliary and pancreatic applications.Abdominal radiology (New York) · 2025Review
- Predicting treatment response and survival in rectal cancer: insights from 18 FDG-PET/MRI post-neoadjuvant therapy.International journal of colorectal disease · 2025Article
- A pelvis MR transformer-based deep learning model for predicting lung metastases risk in patients with rectal cancer.Frontiers in oncology · 2025Article
- Predictive value of 18F-FDG PET/CT metabolic parameters for lymph node metastasis of non-small cell lung cancer.Biomarkers in medicine · 2025Article
- Review
- Article
- Introduction to Special Issue Imaging in Cancer Diagnosis.Tomography (Ann Arbor, Mich.) · 2024Article
- New Trends and Advances in MRI and PET Hybrid Imaging in Diagnostics.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a systematic literature review on the use of [18F]FDG PET/MRI for staging/restaging rectal cancer patients with PubMed, Scopus, and Web of Science, based on the PRISMA criteria. Three authors screened all titles and abstracts and examined the full texts of all the identified relevant articles. Studies containing aggregated or duplicated data, review articles, case reports, editorials, and letters were excluded. Ten reports met the inclusion criteria. Four studies examined T staging and one focused on local recurrences after surgery; the reported sensitivity (94-100%), specificity (73-94%), and accuracy (92-100%) varied only slightly from one study to another. The sensitivity, specificity, and accuracy of [18F]FDG PET/MRI for N staging were 90-93%, 92-94%, and 42-92%. [18F]FDG PET/MRI detected malignant nodes better than MRI, resulting in treatment change. For M staging, [18F]FDG PET/MRI outperformed [18F]FDG PET/CT and CT in detecting liver metastases, whereas it performed worse for lung metastases. The results of this review suggest that [18F]FDG PET/MRI should be used for rectal cancer restaging after chemoradiotherapy and to select patients for rectum-sparing approaches thanks to its accuracy in T and N staging. For M staging, it should be associated at least with a chest CT scan to rule out lung metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.